Skip to main content
SpringerLink
Log in

MS: multiple strategies cost effective

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rivas E, et al. beta-Adrenergic blockade does not impair the skin blood flow sensitivity to local heating in burned and nonburned skin under neutral and hot environments in children. Microcirculation 24: e12350, No. 4, May 2017.

    Article  Google Scholar 

  2. Djambazov S, et al. Cost-Effectiveness Analysis of Alemtuzumab for the Treatment of Multiple Sclerosis in Bulgaria, 2016. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PND31, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/70579?pdfid=49853.

  3. Smith A, et al. Cost-Utility Analysis of Alemtuzumab Versus Subcutaneous Interferon Beta-1A for the Treatment of Relapsing-Remitting Multiple Sclerosis: US Payer Perspective. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PND34, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/72321?pdfid=49902.

  4. Zimmermann M, et al. Cost-Utility of Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND35, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/73538?pdfid=49882.

  5. Ordonez JE. Cost-Utility Analysis of Pegylated Interferon Beta-1A Versus Interferons Beta-1A and Beta-1B in Patients with Relapsing-Remitting Multiple Sclerosis in Colombia. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND36, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/72004?pdfid=49892.

  6. Ordonez JE. Dimethyl Fumarate Versus Fingolimod and Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Colombia: a Cost-Utility Analysis. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND37, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/72008?pdfid=49893.

  7. Sandberg EA, et al. Choice of Treatments and Willingness to Pay to Insure for Multiple Sclerosis Disease Modifying Therapies. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND53, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/73474?pdfid=49874.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

MS: multiple strategies cost effective. PharmacoEcon Outcomes News 780, 25–26 (2017). https://doi.org/10.1007/s40274-017-4077-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4077-6

Search

Navigation